2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS

2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS

There is provided a compound of formula (I) and the pharmaceutically acceptable salts and esters thereof wherein X1 , X2, R1 , R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents. la présente invention concerne un composé répondant à la formule (I) ainsi q...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LIU, JIN-JUN, LOVEY, ALLEN JOHN, KONG, NORMAN, PIZZOLATO, GIACOMO, GRAVES, BRADFORD JAMES, WOVKULICH, PETER MICHAEL, SO, SUNG-SAU, ROBERTS, JOHN LAWSON, VU, BINH THANH, DING, QINGJIE
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There is provided a compound of formula (I) and the pharmaceutically acceptable salts and esters thereof wherein X1 , X2, R1 , R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents. la présente invention concerne un composé répondant à la formule (I) ainsi que des sels et esters pharmaceutiquement acceptables de celui-ci, X1 , X2, R1 , R2, R3, R4, R5 et R6 étant tels que décrits dans le présent document. Lesdits composés sont actifs en tant qu'agents anticancéreux.